OF SHARED RESOURCE Since the founding of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) in 1985, the primary mission of the APC has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing by-cost, state-of-the-art services. The APC provides state-of-the-art equipment and facilities in 1200 square feet of laboratory space on the first floor of the SKCCC Cancer Research Building (CRBI). The location of the APC is adequate to meet the needs of the SKCCC investigators to investigate the pharmacokientics, pharmacodynamics, and pharmacogenetics of anticancer agents. Services include pharmacological trial design, analytical method development and validation, pharmacokinetic and pharmacodynamic data analysis and interpretation, and consultation for design of in vitro drug metabolism, protein binding studies, non-invasive phenotypic probes for drug metabolizing enzymes, and pharmacogenetic studies. The APC houses five UPLC/HPLC instruments with a UV/fluorescence (1), triple stage quadruple mass spectrometer (3), and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC sample analysis has steadily increased since 2005 and is analyzing more than 4,000 samples/year with 20 new methods developed/year, serving over 26 faculty members who are members of eleven CCSG Programs with the majority of the users having peer-reviewed funding. The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design, and data interpretation, and who ensure that instrumentation is suitably maintained and available for investigators seeking support from the APC Lay: The ability to quantify drugs and their metabolites in cells, plasma, and tissues is an essential need in research aimed at determining how drugs go through the body and the link to the drug's effects both in animals and in humans. The Analytical Pharmacology Core laboratory provides services to design, conduct, and interpret this data. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661001
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$175,331
Indirect Cost
$67,322
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Zeidner, Joshua F; Zahurak, Marianna; Rosner, Gary L et al. (2015) The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma 56:128-34
Penet, Marie-France; Shah, Tariq; Bharti, Santosh et al. (2015) Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res 21:386-95
Sharabi, Andrew B; Nirschl, Christopher J; Kochel, Christina M et al. (2015) Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res 3:345-55
Peltonen, Karita; Colis, Laureen; Liu, Hester et al. (2014) A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25:77-90
DeZern, Amy E; Guinan, Eva C (2014) Aplastic anemia in adolescents and young adults. Acta Haematol 132:331-9
Paller, Channing J; Wissing, Michel D; Mendonca, Janet et al. (2014) Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 3:1322-35
Maldonado, Leonel; Teague, Jessica E; Morrow, Matthew P et al. (2014) Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 6:221ra13
Schweizer, Michael T; Antonarakis, Emmanuel S (2014) Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl 16:334-40
Huang, Peng; Ou, Ai-hua; Piantadosi, Steven et al. (2014) Formulating appropriate statistical hypotheses for treatment comparison in clinical trial design and analysis. Contemp Clin Trials 39:294-302
Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81

Showing the most recent 10 out of 357 publications